| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
|
J Natl Cancer Inst
|
2005
|
6.03
|
|
2
|
Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
|
J Natl Cancer Inst
|
2003
|
3.08
|
|
3
|
A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women.
|
J Natl Cancer Inst
|
2002
|
1.83
|
|
4
|
A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
1.82
|
|
5
|
Viral load of human papillomavirus and risk of CIN3 or cervical cancer.
|
Lancet
|
2002
|
1.78
|
|
6
|
Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
|
J Clin Oncol
|
2012
|
1.78
|
|
7
|
Diagnoses and outcomes in cervical cancer screening: a population-based study.
|
Am J Obstet Gynecol
|
2004
|
1.64
|
|
8
|
Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies.
|
J Infect Dis
|
2002
|
1.58
|
|
9
|
Prostate cancer screening and mortality: a case-control study (United States).
|
Cancer Causes Control
|
2004
|
1.54
|
|
10
|
The health care costs of cervical human papillomavirus--related disease.
|
Am J Obstet Gynecol
|
2004
|
1.39
|
|
11
|
Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.
|
J Clin Oncol
|
2010
|
1.37
|
|
12
|
A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer.
|
Cancer Causes Control
|
2010
|
1.35
|
|
13
|
Abnormal outcomes following cervical cancer screening: event duration and health utility loss.
|
Med Decis Making
|
2007
|
1.28
|
|
14
|
Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.
|
Prostate
|
2003
|
1.26
|
|
15
|
Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions.
|
J Clin Microbiol
|
2007
|
1.22
|
|
16
|
Pap screening in a U.S. health plan.
|
Cancer Epidemiol Biomarkers Prev
|
2004
|
1.22
|
|
17
|
Age-appropriate use of human papillomavirus vaccines in the U.S.
|
Gynecol Oncol
|
2009
|
1.16
|
|
18
|
Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
|
Ann Pharmacother
|
2006
|
1.15
|
|
19
|
Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible.
|
J Clin Microbiol
|
2002
|
1.14
|
|
20
|
Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
|
Support Care Cancer
|
2013
|
1.10
|
|
21
|
Comparison of documented and recalled histories of exposure to diagnostic x-rays in case-control studies of thyroid cancer.
|
Am J Epidemiol
|
2003
|
1.06
|
|
22
|
Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer.
|
J Clin Microbiol
|
2003
|
1.05
|
|
23
|
PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma.
|
Cancer Res
|
2008
|
1.05
|
|
24
|
Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women.
|
Cancer
|
2002
|
1.03
|
|
25
|
Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies.
|
Cancer
|
2008
|
0.98
|
|
26
|
Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.97
|
|
27
|
Efficacy of screening in preventing cervical cancer among older women.
|
Cancer Causes Control
|
2013
|
0.97
|
|
28
|
Human papillomavirus prevalence in women who have and have not undergone hysterectomies.
|
J Infect Dis
|
2006
|
0.96
|
|
29
|
Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity.
|
Sex Transm Dis
|
2002
|
0.95
|
|
30
|
Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification.
|
Int J Gynecol Pathol
|
2008
|
0.95
|
|
31
|
Levels of zinc, selenium, calcium, and iron in benign breast tissue and risk of subsequent breast cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
0.92
|
|
32
|
Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study.
|
Mutat Res
|
2007
|
0.90
|
|
33
|
Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
|
Support Care Cancer
|
2014
|
0.89
|
|
34
|
High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.
|
Prostate
|
2012
|
0.85
|
|
35
|
Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells.
|
Mol Endocrinol
|
2008
|
0.85
|
|
36
|
Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan.
|
Int J Cancer
|
2012
|
0.82
|
|
37
|
Human leukocyte antigen class I alleles and cervical neoplasia: no heterozygote advantage.
|
Cancer Epidemiol Biomarkers Prev
|
2002
|
0.80
|
|
38
|
Risk factors for breast cancer in women biopsied for benign breast disease: a nested case-control study.
|
Cancer Epidemiol
|
2010
|
0.80
|
|
39
|
A Cohort Study of p53 Mutations and Protein Accumulation in Benign Breast Tissue and Subsequent Breast Cancer Risk.
|
J Oncol
|
2011
|
0.78
|
|
40
|
Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.
|
BMC Health Serv Res
|
2014
|
0.77
|
|
41
|
Response to "Use of cervical cancer screening among insured women: the extent of missed opportunities" [Health Policy 73 (2005) 194-201].
|
Health Policy
|
2005
|
0.76
|